Member Directory

Chair: Charles Flexner

Objectives:

  • Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
  • Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
  • Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University.

Conflict of Interest: Dr. Blaschke has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Durect Corporation, Cupertino California

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine.

Conflict of Interest: I am a member of a Data Monitoring Committee for Merck & Co.

Conflict of Interest: No disclosures.

Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. 

Conflict of Interest: No disclosures.

Jeffrey M. Jacobson, MD is Professor of Medicine at Case Western Reserve University and Principal Investigator of the Case AIDS Clinical Trials Unit. 

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Andy Kaytes has been an active member and currently co-chairs the Community Advisory Board at the University of California San Diego’s Antiviral Research Center since 2004.

Conflict of Interest: Andy has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Bristol Myers Squibb

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. 

Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center.

Conflict of Interest: Dr. Mirochnick has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck, ViiV, Gilead, ReViral.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. 

Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare

Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. 

Conflict of Interest: None disclosed.

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.

Conflict of Interest: Dr. Swindells reports research grants to her institution from ViiV Healthcare.

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine.

Conflict of Interest: I have no real or apparent conflicts of interest to report.